Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study

Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study

Regularly scheduled intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are essential to maintaining and/or improving many ocular conditions including: neovascular age-related macular degeneration (nAMD), diabetic retinopathy, and retinal vein occlusions with macular edema (R...

Full description

Bibliographic Details
Main Authors: Emerson, G.G (Author), Koozekanani, D.D (Author), Montezuma, S.R (Author), Mundae, R. (Author), Naravane, A.V (Author), Nazari, H. (Author), Santilli, C. (Author), van Kuijk, F.J.G.M (Author), Yamanuha, J. (Author), Zhou, Y. (Author)
Format: Article
Language:English
Published: Public Library of Science 2021
Subjects:
adult
Adult
aged
Aged
Aged, 80 and over
angiogenesis inhibitor
Angiogenesis Inhibitors
Article
controlled study
coronavirus disease 2019
COVID-19
Current Procedural Terminology
diabetic macular edema
diabetic retinopathy
Diabetic Retinopathy
drug effect
epidemiology
female
Female
follow up
human
Humans
isolation and purification
lockdown
macular edema
Macular Edema
major clinical study
male
Male
middle aged
Middle Aged
Minnesota
optical coherence tomography
pandemic
Pandemics
patient identification
Pilot Projects
pilot study
procedures
proliferative diabetic retinopathy
psychology
quarantine
Quarantine
retina disease
retina vein occlusion
Retinal Diseases
Retinal Vein Occlusion
Retrospective Studies
retrospective study
SARS-CoV-2
therapy delay
time to treatment
Time-to-Treatment
treatment outcome
Vascular Endothelial Growth Factors
vasculotropin
vasculotropin inhibitor
very elderly
visual acuity
Visual Acuity
wet macular degeneration
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items